期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 97, 期 13, 页码 7609-7614出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.97.13.7609
关键词
amyloid beta-protein; imaging; senile plaques
Strategies for treating Alzheimer's disease (AD) include therapies designed to decrease senile plaque (SP) formation and/or promote clearance of SPs. but clinical trials of these treatments are limited by the lack of effective methods to monitor changes in plaque burden in the brains of living AD patients. However. because SPs are extracellular deposits of amyloid-beta peptides (A beta), it may be possible to eventually develop radioligands that cross the blood-brain barrier (BBB) and label SPs so they can be visualized by current imaging methods. As a first step toward the generation of such a radioligand, we developed a probe, [(trans,trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene(BSB)], and we report here that BSB has the following properties essential for a probe that can detect SPs in vivo, First, BSB sensitively labels SPs in AD brain sections. Second. BSB permeates living cells in culture and binds specifically to intracellular A beta aggregates. Third, after intracerebral injection in living transgenic mouse models of AD amyloidosis. BSB labels SPs composed of human A beta with high sensitivity and specificity. fourth, BSB crosses the BBB and labels numerous AD-like SPs throughout the brain of the transgenic mice after i.v. injection. Thus, we conclude that BSB is an appropriate starting point for future efforts to generate an antemortem diagnostic for AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据